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1.  INTRODUCTION
Until the advent of targeted therapies, interferon alfa 
and interleukin-2 represented the standards of care 
for patients with metastatic renal cell carcinoma 
(mr c c ). Since 2006, six randomized controlled trials 
have demonstrated the efficacy of five novel targeted 
therapies in primarily clear-cell mr c c  patients 1–6.
First, in previously untreated patients (n = 750), 
Motzer et al. showed that, as compared with inter-
feron, sunitinib improves median progression-free 
survival (p f s) to 11 months from 5 months [hazard 
ratio (h r ): 0.42; p < 0.001] 1. Then, in patients previ-
ously exposed to interferon (n = 903), Escudier et al. 
showed that, as compared with placebo, sorafenib 
improves median p f s to 5.5 months from 2.8 months 
(h r : 0.44; p < 0.001) 2. Subsequently, in previously 
untreated patients (n = 626), Hudes et al. showed that, 
as compared with interferon, temsirolimus improves 
median overall survival (o s ) to 10.9 months from 
7.3 months (h r : 0.73; p = 0.008) 3. Thereafter, in 
previously untreated patients (n = 649),  Escudier et al. 
showed that, as compared with interferon alone, be-
vacizumab combined with interferon improves 
median p f s to 10.2 months from 5.4 months (h r : 0.63; 
p = 0.0001) 4. The efficacy of bevacizumab was cor-
roborated by Rini et al. (n = 732), who observed an 
increase in p f s to 8.5 months from 5.2 months (h r : 
0.71; p < 0.0001) 5. Most recently, in patients who 
experienced failure of one or more previous targeted 
therapies (n = 410), Motzer et al. showed that, as 
compared with placebo, everolimus improves me-
dian p f s to 4.0 months from 1.9 months (h r : 0.31; 
p < 0.0001) 6. Taken together, these findings illustrate 
the efficacy of targeted therapies in first, second, and 
subsequent treatment lines.
In the present manuscript, we focus on sorafenib, 
and we review data supporting its use in the first, second, 
and subsequent treatment lines. Moreover, we show data 
that support the use of sorafenib in patients with non-
clear-cell histology. Finally, we review data demon-
strating increased efficacy when the dose of sorafenib 
is escalated beyond the usual 400 mg twice daily.
ABSTRACT
Purpose
Sorafenib represents one of the two standards of 
care for patients with metastatic renal cell carcinoma 
(mr c c). In the present review, we provide informa-
tion regarding the use of sorafenib in first and second 
lines. We also describe results for dose escalation 
strategies. Finally, we provide data addressing the 
efficacy of sorafenib in patients with mr c c  of non-
clear-cell histology.
Recent Findings
Sorafenib is a valid first-line agent. Sorafenib re-
sponse rates and toxicity are not affected by patient 
age or site of metastasis. The sequence of first-line 
sorafenib followed by second-line sunitinib resulted 
in a longer duration of response than did the oppo-
site sequence. Sorafenib efficacy in first-line therapy 
can be potentiated by co-administration of low-dose 
interferon. Moreover, in first-line therapy, impres-
sive response rates were recorded when the dose of 
sorafenib was escalated beyond the standard 400 mg 
twice daily. Similarly impressive response rates were 
observed with dose escalation in second-line therapy. 
It is notable that dose escalation after failure of stan-
dard sorafenib dose also prolongs progression-free 
survival. Finally, the efficacy of sorafenib is not 
limited to clear-cell histology, but also applies to 
chromophobe and papillary mr c c  variants.
Summary
Sorafenib is a highly effective and well-tolerated 
agent for first- and second-line patients with clear-
cell, chromophobe, or papillary mr c c  variants.
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2.  CURRENT GUIDELINES IN THE TREATMENT 
OF MRCC
The National Comprehensive Cancer Network 
(n c c n ) 7, the European Association of Urology 8, and 
the European Organisation for Research and Treat-
ment of Cancer (e o r t c) 9 guidelines all suggest the 
use of sunitinib in the first line for favourable- and 
intermediate-prognosis mr c c . In patients with poor-
prognosis mr c c, temsirolimus is recommended in 
the first line.
Based on the findings of the Escudier et al. ran-
domized controlled trial of sorafenib versus placebo 
after cytokine failure, treatment with sorafenib is rec-
ommended in patients with clear-cell histology after 
failure of cytokine therapy. The standard recommen-
dation for sorafenib use is therefore in second-line 
therapy 2. However, according to the e o r t c and n c c n  
recommendations, select patients may be candidates 
for sorafenib in first-line treatment 7,9.
3.  EVIDENCE OF SORAFENIB EFFICACY AND 
FAVOURABLE TOXICITY
3.1  Phase I Sorafenib Studies
Sorafenib is a multikinase inhibitor, specifically tar-
geting tumour cells and tumour vessels. In its original 
design, the molecule was developed as a specific 
inhibitor of the Raf-1 protein kinase. In subsequent 
studies, sorafenib was found to have selective activ-
ity against B-Raf, vascular endothelial growth factor 
receptors 2 and 3, platelet-derived growth factor 
receptor β, Flt-3 (f m s -like tyrosine kinase 3), and 
stem-cell growth factor C-Kit 2,10.
The safety and toxicity of sorafenib were investi-
gated in four phase i studies (n = 173). Doses ranged 
from 50 mg to 800 mg once or twice daily 11–14. 
The maximal tolerated dose was 400 mg given 
continuously twice daily. Dose-limiting toxicities—
grade 3 or higher according to the National Cancer 
Institute (n c i ) Common Toxicity Criteria (c t c ) ver-
sion 2.0 15—consisted of diarrhea (2 of 6 at 800 mg 
twice daily), fatigue (1 of 6 at 800 mg twice daily), 
and skin toxicity (4 of 14 at 600 mg twice daily). 
Based on the efficacy-to-toxicity ratio, the 400-mg 
twice-daily dosage, which was associated with a 
manageable toxicity profile, was recommended as 
the target dose for future trials.
3.2  Phase II Sorafenib Trials
The efficacy of sorafenib was demonstrated in a 
phase ii placebo-controlled randomized discontinu-
ation trial of sorafenib in 202 patients with mr c c . 
Sorafenib-exposed patients had a significantly 
prolonged p f s (24 weeks vs. 6 weeks, p = 0.0087). 
Moreover, during the run-in phase, an investigator-
assessed twice-daily dimensional tumour assessment 
in 193 evaluable patients (from among all patients 
exposed to sorafenib) showed stable disease (s d) in 
34% and partial responses (p rs) in 36% 16.
3.3  Phase III Sorafenib Studies
A phase iii sorafenib trial was conducted in 903 
patients previously treated with immunotherapy; 
these patients were randomized either to placebo or 
to sorafenib 400 mg twice daily. The most common 
adverse events of any grade [according to the n c i  
Common Terminology Criteria for Adverse Events 
(c t c a e ) version 3.0 17] were diarrhea (43%), rash or 
desquamation (40%), fatigue (37%), hand–foot skin 
reaction (30%), alopecia (27%), and nausea (23%). 
The most frequent grades 3 and 4 toxicities included 
hand–foot skin reaction (6%), fatigue (5%), dyspnea 
(4%), and hypertension (4%). Grade 3 or 4 anemia 
occurred in 3% of patients, and grade 3 or 4 lym-
phopenia occurred in 13% of patients. Neutropenia 
was not reported. Cardiac ischemia or infarction oc-
curred in 3% of patients 2.
Relative to placebo, sorafenib improved median 
p f s to 5.5 months from 2.8 months (h r : 0.44; 
p < 0.001) 2. The efficacy of sorafenib with regard to 
quality-of-life outcomes and toxicity profile were all 
unaffected by patient age 18–21. Similarly, sorafenib 
efficacy was unrelated to the site of metastasis 22.
3.3.1  Pitfalls in the Interpretation of Cancer Control 
Features in the Phase III Sorafenib Trial
In accordance with the ethical considerations that 
apply to placebo-controlled trials, placebo patients 
who demonstrate disease progression are allowed to 
cross over to the active treatment arm after disease 
progression has been documented. Such a measure 
reduces the recorded efficacy of active therapy and 
dilutes its effect. This phenomenon affected o s  and 
p f s data within the sorafenib trial 19.
For example, before placebo-arm patients crossed 
over to the sorafenib arm, the initial analysis demon-
strated a reduction in overall mortality that resulted 
in a h r  of 0.72 (p = 0.02) 2. In the analysis that was 
performed after crossover of the placebo patients 
into the sorafenib arm, the h r  decreased to 0.77 
(p = 0.02) 2. Finally, at completion of the study, when 
even more placebo crossovers had occurred, the h r  
further decreased to 0.88, with a loss of statistical 
significance as evidenced by p = 0.146 19.
Taken together, these observations illustrate the 
confounding effect of crossover that cannot be con-
trolled with statistical tools. Crossovers confound 
the magnitude and significance of cancer control 
measures so profoundly that o s  and p f s measures per-
formed after crossover cannot be validly interpreted. 
It is questionable whether a non-censored survival 
analyses should be performed after crossover from 
a placebo arm has occurred. Consequently, study 
designs with censoring at crossover might represent SORAFENIB IN THE MANAGEMENT OF METASTATIC RCC
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a better alternative. In the analysis of sequential 
therapies, o s  and p f s should be invariably interpreted 
before any crossover.
4.  FIRST-LINE USE OF SORAFENIB
First-line use of sorafenib was examined in only 
one randomized study, a phase ii trial conducted by 
Escudier et al. (n = 189) that was reported in 2009 23. 
Its design addressed p f s and toxicity of sorafenib 
relative to interferon. The median p f s was similar 
in both trial arms, 5.7 months with sorafenib as 
compared with 5.6 months with interferon [h r (in-
terferon/sorafenib): 0.88; p = 0.5]. The disease 
control rate [complete response (c r) + p r + s d ≥ 
6 weeks: 79.4%] achieved with sorafenib was 
higher than that achieved with interferon (64.1%, 
p = 0.006). Health-related quality of life was better 
with sorafenib than with interferon.
Despite the randomized nature of this trial, several 
caveats limit its value. First, the interferon data were 
inconsistent with other median p f s values for inter-
feron. For example, in the p e r c y  Quattro study by 
Negrier et al. 24, a median p f s of 3.4 months was re-
corded for patients exposed to interferon. Second, the 
Escudier et al. study 23 was underpowered because of 
its premature closure. The p f s findings are therefore 
difficult to interpret.
Two phase ii studies examined the combination 
of sorafenib with interferon in first-line therapy 25,26. 
Ryan et al. 25 (n = 62) co-administered 400 mg twice-
daily sorafenib with interferon 10×106 IU. This com-
bination resulted in a median p f s of 7.0 months, but 
toxicity was dose-limiting. Tannir et al. 26 (n = 72) ex-
plored the efficacy of first-line sorafenib 400 mg twice 
daily with low-dose interferon (0.5×106 IU twice 
daily) and recorded a p f s duration of 7.6 months. 
The toxicity was marginally more elevated in the 
combined sorafenib–interferon arm, with a 61.5% 
dose reduction rate as compared with a 51.2% rate 
for sorafenib alone. These data illustrate a promising 
increase in the efficacy of first-line sorafenib when 
co-administered with interferon (p f s: 5.7 months vs. 
7.0–7.4 months) 25,26. Moreover, only a marginal in-
crease in toxicity should be expected when interferon 
is co-administered in a twice-daily low dose.
5.  SORAFENIB DOSE ESCALATION
Based on phase i and ii data, the standard dose of 
sorafenib was defined at 400 mg twice daily 2. This 
dosing is usually very well tolerated and allows for 
safe dose escalation in most patients 2. Two studies 
assessed the effect of dose escalation on response 
rates in first- or second-line therapy 27,28.
In 2007, Amato et al. 27 studied 44 patients 
previously exposed to a maximum of one systemic 
therapy and recorded a median p f s of 8.4 months. 
Overall, 91% of the patients tolerated dose escalation 
up to 1200 mg or 1600 mg daily. Impressive antitu-
mour activity was observed, as shown by 8 c r s and 
14 p rs for a total c r+p r rate of 52%. Because most 
of the adverse events were grade 1 or 2, toxicity was 
highly acceptable.
In 2008, Amato et al. 28 studied a second cohort 
of 23 patients who had previously been exposed to a 
maximum of one cytokine therapy. Of those patients, 
87% had no exposure to any previous therapy. Over-
all, 22 of 23 patients tolerated escalation to 1200 mg 
daily, and 14 of 14 patients tolerated 1600 mg daily. 
An equally impressive p f s of 7.7 months was record-
ed. However, the combined c r +p r rate of 32% was 
lower than that seen in the initial study (52%). Again, 
most of the adverse events were grade 1 or 2.
Recently, Escudier et al. 23 (n = 189) studied the 
effect of dose escalation in second-line therapy af-
ter failure of sorafenib 400 mg twice-daily dosing. 
At progression, the dose was escalated to 600 mg 
twice daily, and a 41.9% tumour response rate was 
recorded. An additional 39.5% of patients showed s d. 
The median p f s was 3.6 months despite initial pro-
gression on sorafenib. The combined median p f s of 
5.7 months after first-line standard sorafenib dosing, 
and the subsequent median p f s of 3.6 months after 
sorafenib dose escalation, resulted in an impressive 
9.3 months of combined median p f s, with an overall 
response rate of 84%.
In a multicentre prospective trial, Shepard et al. 29 
also studied the effect of sorafenib dose escalation 
after failure of regular sorafenib 400 mg twice-daily 
dosing. Patients (n = 42) had previously experienced 
progression after sunitinib or bevacizumab-based 
therapy. The sorafenib dose was escalated to 600 mg 
or 800 mg twice daily in 9 patients; these patients 
subsequently required dose reductions. Overall, this 
study demonstrated a tumour burden reduction rate 
of 31% and a s d rate of 53%. Median p f s was 3.7 
months, which is consistent with the findings reported 
by Escudier et al. (p f s: 3.6 months). Side effects were 
manageable, and the toxicity profile of dose-escalated 
sorafenib in this study was similar to that seen in 
other trials 2,23.
Taken together, the dose escalation data show that 
in the first line, sorafenib delivered at doses that ex-
ceed the 400 mg twice-daily standard dose may result 
in a c r  rate of up to 20% 23. Such a high proportion 
of c r s has never previously been reported. However, 
those promising results need to be corroborated in 
large-scale trials. In the second line, sorafenib dose es-
calations are equally promising and demonstrate that 
the median p f s may be increased by at least 3 months 
if either sorafenib or another targeted therapy was 
administered before dose escalation 23,27–29.
6.  SORAFENIB SEQUENTIAL THERAPY
Data from a randomized controlled trial confirm the 
efficacy of sequential sorafenib therapy after cytokine GUEVREMONT et al.
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failure 2. In contemporary patients, cytokines are 
almost never used as monotherapy, particularly in 
the light of the p e r c y Quattro data that showed the 
efficacy of interferon to be equivalent to that of me-
droxyprogesterone 24. However, data on the use of 
sorafenib after failure of other targeted therapies 
(which could justify contemporary guidelines for 
second-line use) are scarce.
Knox et al. 20 were the first to report on efficacy of 
sorafenib sequential therapy from the North Ameri-
can Advanced Renal Cell Carcinoma Sorafenib 
Access Program (a r c c s ). Within that program, 
1255 patients received sorafenib as second-line or 
subsequent therapy. Interferon alfa, interleukin-2, 
bevacizumab, sunitinib, and thalidomide were pre-
viously administered to 646 (51%), 522 (42%), 290 
(23%), 24 (2%), and 142 (11%) of those patients 
respectively. For patients taking sorafenib in the 
second or a subsequent line, the rates of p r and s d 
were 3% and 81% respectively 20. Those rates com-
pared very favourably with the 4% p r and 79% s d 
rates seen in first-line sorafenib patients within the 
same program 20.
Sablin et al. 30 were the first to report on differ-
ences in response rates according to the sequence 
of agents used. In that study, sequential therapy 
with first-line sorafenib and subsequent sunitinib 
(n = 68) was associated with better results (me-
dian p f s: 26 weeks) than was first-line sunitinib 
with subsequent sorafenib (n = 22; median p f s: 
22 weeks) 30.
Recently, Dudek et al. 31 (n = 49) reported on the 
use of sequential therapy with sorafenib and sunitinib. 
Their data showed a combined median p f s of 78 weeks 
for patients initially treated with sorafenib followed 
by sunitinib as compared with 37 weeks for patients 
initially treated with sunitinib followed by sorafenib 
(risk ratio: 3.0; p = 0.016). The authors explained the 
observed difference in survival as being the result of 
a stronger resistance to targeted therapy after initial 
sunitinib exposure as compared with after initial 
sorafenib exposure.
The findings of Sablin et al. 30 and Dudek et al. 31 
are consistent with the report by Motzer et al. 6 on the 
efficacy of everolimus after failure of previous target-
ed therapy. Motzer et al. demonstrated that everolimus 
results in a p f s of 5.9 months after sorafenib failure 
as compared with 3.4 months after sunitinib failure 6. 
In consequence, superior p f s results can be expected 
if sorafenib instead of sunitinib is used as the first 
targeted therapy.
Most recently, Tamaskar et al. 32 reported a com-
bined p r+s d rate of 71% in 14 patients exposed to 
sorafenib after various targeted therapy failures.
Taken together, these findings support the use 
of first-line sorafenib as recommended by the n c c n  
and e o r t c guidelines 7,9. However, the sequence 
of targeted therapies remains to be corroborated in 
larger-scale trials.
7.  USE OF SORAFENIB IN NON-CLEAR-CELL 
RENAL CARCINOMA
In the randomized phase iii sorafenib placebo-con-
trolled trial, 100% of patients harboured clear-cell his-
tology 2. Since the publication of that report, a number 
of investigators have showed that excellent response 
rates may also be expected in patients with the papil-
lary or chromophobe histologic variants 2,20,32,33.
Knox et al. 20 represent the first investigator group 
to address the efficacy of sorafenib in non-clear-cell 
histology. The a r c c s  expanded access program in-
cluded 118 individuals with papillary and 18 with 
chromophobe histology. The combined p r+s d rate 
for papillary mr c c  was 80% as compared with 95% 
for the chromophobe variant 20.
Choueiri et al. 33 showed a 68% s d rate in 28 
individuals with papillary mr c c . As with the a r c c s  
data 30, the p r+s d rate in chromophobe non-clear-cell 
r c c  patients (n = 5) was high at 100%.
Predominantly based on Choueiri et al. 33 and the 
a r c c s  20 data, the efficacy of sorafenib in papillary 
and chromophobe mr c c  variants may be expected to 
parallel the efficacy reported for clear-cell histology. 
The extent to which this effect may be modified by 
treatment line (first vs. second vs. subsequent), or by 
co-administration of biologic response modifiers such 
as interferon, remains to be seen.
8.  CONCLUSIONS
In the present manuscript, we have demonstrated that 
sorafenib represents a valid first-line agent 23,24,27. 
The sequence of first-line sorafenib followed by 
second-line sunitinib results in longer response 
duration than does the opposite sequence 20. More-
over, sorafenib efficacy in first-line therapy can 
be potentiated by co-administration of low-dose 
interferon 25. Also, in first-line therapy, impressive 
response rates have been recorded when the dose of 
sorafenib was escalated beyond the standard 400 mg 
twice daily 27,28. Similarly impressive responses 
were observed with dose escalation in second-line 
therapy 27,28. Notably, dose escalation after failure 
of a standard sorafenib dose also prolonged p f s  23. 
Finally, the efficacy of sorafenib is not limited to 
clear-cell histology, but also applies to the chro-
mophobe and papillary mr c c variants 20,33. Last 
but not least, a comparison of toxicities between 
sorafenib, sunitinib, and temsirolimus demonstrated 
that sorafenib is associated with the lowest toxicity 
rates, which further validates the use of sorafenib 
as the initial targeted agent 34.
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